As the global robotics sector sees surging investment, a former star has collapsed spectacularly. Recently, investors in U.S. surgical robotics company Vicarious Surgical voted to cease operations and proceed with bankruptcy liquidation. The company, once hailed as a challenger to the da Vinci surgical system, raised approximately $300 million cumulatively and attracted investment from Bill Gates, Yahoo founder Jerry Yang, and other prominent figures—only to burn through its last reserves as its product repeatedly failed to reach commercialization.
Vicarious Surgical’s story began with a science fiction film. Inspired by the 1966 movie Fantastic Voyage, in which five doctors are shrunk and injected into a patient’s body to perform surgery, the company was founded in 2014 by MIT mechanical engineering graduates Adam Sachs and Sammy Khalifa, alongside Barry Greene, a surgeon with years of laparoscopic experience. Sachs and Khalifa had both worked as engineers at Apple, bringing a consumer-electronics miniaturization mindset to the surgical robotics field from day one.
The company’s robotic arm design featured nine degrees of freedom—more flexible than the da Vinci system’s seven—allowing it to reach any corner of a patient’s abdominal cavity. An even bolder innovation was integrating VR technology into the surgical workflow: a miniature robot equipped with two robotic arms and a 360-degree camera would enter the abdomen through an incision smaller than 1.5 centimeters, while the surgeon operated remotely wearing a VR headset. This concept quickly captivated capital markets, with Bill Gates, former Google CEO Eric Schmidt, Jerry Yang, and Khosla Ventures among the prominent backers.
In 2021, Vicarious went public via SPAC on the U.S. stock market, with its market cap briefly exceeding $1.2 billion. The following year, its product was named to Time magazine’s Best Inventions of 2022 and became the first surgical robot to receive Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). Yet going public turned out to be the company’s last moment of glory.
Engineering the product for real-world use proved far more difficult than anticipated. To make the robotic arm mimic a human hand, Vicarious adopted a decoupled actuation scheme, resulting in extreme structural complexity and poor yield control. The precision of a single system was comparable to a Swiss watch, making stable mass production of FDA-compliant units nearly impossible. Meanwhile, the two-arm design meant many surgical procedures could not be completed smoothly, and the VR headset was criticized as more gimmick than utility—prolonged wear actually increased surgeon fatigue. The founders’ engineering mindset produced impressive technical specifications but severely underestimated the difficulties of medical device development cycles, regulatory approval, and clinical validation.
Financial data paints a clear picture of the company’s predicament. In 2024 and 2025, Vicarious posted losses of $63 million and $50.2 million, respectively. By the end of March this year, the company had only approximately $3.7 million remaining in cash, cash equivalents, and short-term investments, while still losing $7.3 million that quarter. After its average market cap fell below $15 million for 30 consecutive trading days, the company received a delisting notice from the NYSE. With no new funding or buyer in sight, bankruptcy liquidation became the only option.
The company’s assets will be transferred to a third party, “Vicarious Liquidation LLC,” to settle debts. For shareholders who invested heavily, a near-total loss is virtually certain. Ahead of the special shareholder meeting, the company acknowledged it “cannot predict whether any residual funds will be available to repay investors.”
Vicarious’s collapse is not an isolated case. Across the global robotics industry, commercialization challenges are spreading. Last November, Silicon Valley humanoid robotics startup K-Scale Labs folded after three funding rounds when it could not sustain operations until mass production. Earlier, U.S. consumer robotics pioneer iRobot also filed for bankruptcy protection.
An unspoken truth in the industry is that while robot demo videos are always impressive, customers lack a compelling reason to buy. The vast majority of robots today are sold to laboratories, university robotics departments, science museum exhibits, and data collection centers; very few are actually working on production lines. An industrial-grade robot costs hundreds of thousands of yuan at minimum, and it may take a company four to five years to recoup the investment. The home-use scenario is even more distant. According to Stanford University’s 2026 AI Index Report, humanoid robots achieved only a 12.4% success rate in completing 1,000 household tasks in real homes, though the figure reached 89.4% in simulated environments.
Cao Wei, a partner at BlueRun Ventures, commented that emerging industries typically go through two phases: a league phase where everyone can raise money and no one gets eliminated, followed by a knockout phase triggered by structural changes in the external market, where long-term hard capabilities in productization and commercialization become decisive. “Capital markets are inherently cyclical. Today’s embodied AI companies are still some distance from true productization. To survive the coming risk period, they need either ample cash or an outstanding product.”
Vicarious’s bankruptcy serves as a wake-up call for the entire embodied AI sector. This seemingly endless game inspires hope in everyone, but the core challenge remains solving real problems. A more pragmatic, grounded approach may be the only way to avoid going from an industry-disrupting milestone to a complete wipeout.
